# PRODIGE 4 (NCT00112658)

> Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

No report yet. It can be ordered.

- Drugs tested: FOLFIRINOX
- Indication: metastatic pancreatic cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00112658
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: UNICANCER
- Conditions: Pancreatic Cancer
- Interventions: fluorouracil; gemcitabine hydrochloride; irinotecan hydrochloride; leucovorin calcium; oxaliplatin
- Enrollment: 342
- Primary outcome: Objective response rate (Phase II)
- Primary outcome: Survival (Phase III)

## Indexed commentary on PRODIGE 4 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14
- Podcasts: 3
- YouTube: 2

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=prodige-4-nct00112658

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00112658", "email": "<work email>"}; the inbox owner confirms by the emailed link.